SNSusan Nahirniak

Susan Nahirniak

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Susan Nahirniak has a total of 318 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • How I treat patients who are refractory to platelet transfusions

    by Susan Nahirniak, Veera Nadarajan, Simon J. Stanworth

    Patients with thrombocytopenia requiring ongoing platelet transfusion support may develop inadequate platelet count increments, referred to as platelet refractoriness (PR), which further complicates their care. The underlying etiologies of PR can be broadly divided into immune and nonimmune causes. A high index of suspicion is required to initiate testing for alloimmunization, and the leading culprit in immune PR is the development of class I HLA antibodies. The approach to diagnosis of immune PR has changed over recent years with new technologies, but questions regarding the clinical significance and interpretation of these methods have not been conclusively answered. The provision of HLA-matched platelets requires close and timely coordination between transfusion services and clinical teams; however, the true impact of their provision on clinical outcomes is not clear. This paper reviews diagnostic and management challenges, appraises the existing data available to support treatment options, and identifies research gaps.


  • Open Access

    Successful ABO incompatible heart transplantation after desensitization therapy in an older child

    by Annemarie Krauss, Lori J. West, Jennifer Conway, Michael Khoury, Susann Nahirniak, Anne Halpin, Mohammed Al Aklabi, Simon Urschel

    Background: ABO‐incompatible heart transplantation (HTx) has become a standard procedure for children below 2 years of age due to an immunologically immature immune system and associated low isohemagglutinin titers.Methods: We report a case of an ABO‐incompatible HTx (recipient blood group O, donor blood group A) at the age of 5 years and 11 months with a fully matured immune system and previously high isohemagglutinin titers that diminished as a result of human leucocyte antigen (HLA) desensitization therapy with rituximab and immunoglobulins.Results: The anti‐A titer at the time of HTx was 1:16 with post‐transplant isoagglutinin titers never exceeding 1:4 without any signs of rejection with now 3 years of post‐HTx follow‐up.Conclusions: ABO isohemagglutinin titers should be routinely assessed in children undergoing desensitization therapy since ABOi transplantation can be considered in selected cases to expand the donor pool with the option of crossing the ABO barrier to find a better‐matched allograft.


  • Open Access

    ABO-Incompatible Heart Transplantation in Older Children Using Immune Modulation

    by A. Krauss, L.J. West, J. Conway, M. Khoury, A. Halpin, S. Nahirniak, M. Al Aklabi, S. Urschel


  • Patient blood management for liver resection: consensus statements using Delphi methodology

    by Julie Hallet, Shiva Jayaraman, Guillaume Martel, Jean-François B. Ouellet, Yulia Lin, Stuart McCluskey, Kaitlyn A. Beyfuss, Paul J. Karanicolas, Kengo Asai, Jeffrey Barkun, et al.


  • Erratum to: Prothrombin Complex Concentrate for Major Bleeding on Factor Xa Inhibitors: A Prospective Cohort Study

    by Sam Schulman, Peter L. Gross, Bruce Ritchie, Susan Nahirniak, Yulia Lin, Lani Lieberman, Marc Carrier, Mark A. Crowther, Indy Ghosh, Alejandro Lazo-Langner, et al.

    In the Original Article by Schulman et al. “Prothrombin Complex Concentrate for Major Bleeding on Factor Xa Inhibitors: A Prospective Cohort Study” (Thromb Haemost 2018;118:842–851) after publication of the article it has come to the corresponding author's attention that the author affiliations were mixed up. The amended author affiliations are as above.


  • Albumin 5% Versus Crystalloids for Fluid Resuscitation in Children After Cardiac Surgery*

    by Adil R. Dingankar, Dominic A. Cave, Vijay Anand, V. Ben Sivarajan, Susan Nahirniak, Cathy Sheppard, Jan Hanot, Gonzalo Garcia Guerra

    Objectives: To determine the clinical benefit of using colloids versus crystalloids for volume resuscitation in children admitted after cardiac surgery. Design: Retrospective pre-/postintervention cohort study. Setting: Stollery Children’s Hospital tertiary care pediatric cardiac ICU. Patients: Children admitted to the pediatric cardiac ICU after cardiac surgery. Interventions: Fluid resuscitation policy change in which crystalloids replaced albumin 5% as the primary fluid strategy for resuscitation after cardiac surgery. Measurements and Main Results: Children who underwent cardiac surgery in the 6 months prior to the policy change (5% albumin group) were compared with children admitted during the 6 months after (crystalloid group). Demographic, perioperative, and outcome variables (fluid intake days 1–4 postoperative, vasoactive therapy, blood products, time to negative fluid balance, renal replacement therapies, mechanical ventilation, pediatric cardiac ICU, and length of stay) were collected. Data were analyzed using linear and logistic multivariate analysis. The study included 360 children. There was no association between fluid group and fluid intake (mL/kg) on day 1 postoperatively (coefficient, 2.84; 95% CI, 5.37–11.05; p = 0.497). However, crystalloid group was associated with significantly less fluid intake on day 2 (coefficient, –12.8; 95% CI, –22.0 to –3.65; p = 0.006), day 3 (coefficient, –14.9; 95% CI, –24.3 to –5.57; p = 0.002), and on the first 48 hours postoperative (coefficient, 10.1; 95% CI, –27.9 to –1.29; p = 0.032). Pediatric cardiac ICU stay (coefficient, –1.29; 95% CI, –2.50 to –0.08; p = 0.036) was shorter for the crystalloid group. There were no significant differences in the time to negative balance, need for renal replacement therapy, mechanical ventilation days, hospital stay, or pediatric cardiac ICU survival. Conclusions: In our study, the use of albumin 5% for resuscitation after cardiac surgery was not associated with less fluid intake but rather the opposite. Albumin administration did not provide measured clinical benefit while exposing children to side effects and generating higher costs to the healthcare system.


  • Quality of Evidence-Based Guidelines for Transfusion of Red Blood Cells and Plasma: A Systematic Review

    by Katerina Pavenski, Simon Stanworth, Mark Fung, Erica M. Wood, Joanne Pink, Michael F. Murphy, Heather Hume, Susan Nahirniak, Kathryn E. Webert, Susano Tanael, et al.


  • Top Cited Papers

    Prothrombin Complex Concentrate for Major Bleeding on Factor Xa Inhibitors: A Prospective Cohort Study

    by Peter L. Gross, Bruce Ritchie, Susan Nahirniak, Yulia Lin, Lani Lieberman, Marc Carrier, Mark A. Crowther, Indy Ghosh, Alejandro Lazo-Langner, Michelle Zondag, et al.

    Oral factor Xa inhibitors are increasingly used for anticoagulation, but there is no approved reversal agent. Prothrombin complex concentrate (PCC) for the management of Xa-inhibitor–associated bleeding has been described in small case series and one cohort study. Patients on apixaban or rivaroxaban, suffering a major bleed, were treated at nine Canadian hospitals as per existing hospital protocol with a fixed dose of PCC 2,000 units and subsequently recruited for a 30-day follow-up. The treating physician evaluated the haemostatic effectiveness as observed during the first day as good, moderate or poor/none, using an assessment guide. Safety outcomes were thromboembolism or death. We recruited 66 patients with major bleeding who were treated with PCC and who were receiving rivaroxaban (56%) or apixaban (44%). The effectiveness was assessed as good in 65% (95% confidence interval [CI], 53–77), moderate in 20% (95% CI, 10–30) and poor/none in 15% (95% CI, 6–24). For the 36 patients with intracranial haemorrhage, the corresponding ratings were 67, 17 and 17%, and for 16 patients with gastrointestinal bleeding they were 69, 12 and 19%, respectively. There were nine deaths (14%) by 30 days, and five (8%) major thromboembolic events. In a post hoc analysis, according to International Society on Thrombosis and Haemostasis criteria, reversal was effective in 68% and ineffective in 32%. For major bleeding associated with oral Xa inhibitors, PCC may have a beneficial effect. The risk of thromboembolism after reversal of anticoagulation in patients with a prothrombotic background has to be taken into account. S. Schulman, B. Ritchie and M. Carrier conceived and designed the study; S. Schulman analysed and interpreted the data; all authors provided study patients, collected data, wrote and gave final approval of the manuscript. * The investigators are listed in Appendix A.


  • Hospital transfusion medicine committees – problems and pitfalls

    by S. Nahirniak

    Hospital Transfusion Medicine Committees (TMCs) are multidisciplinary committees that provide oversight of a variety of clinical activities as they pertain to transfusion medicine and patient care in hospital environments. Across the globe, there are many different standards that provide guidance on the goals, structure and function of hospital transfusion medicine committees but these are not always implemented in the same manner. This review will highlight some of these standards and undertake a high‐level review of the similarities and differences. Awareness of common barriers to success for TMCs will allow strategies to be developed locally to ensure that the TMC functions in the most effective manner to provide high‐quality transfusion medicine care to patients.